Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. develops biopharmaceutical products using a proprietary technology platform for effective oral drug delivery. News about LPCN centers on clinical development of LPCN 1154, an oral brexanolone product candidate for postpartum depression, including trial progress, safety reviews and reported efficacy results.
Company updates also cover TLANDO, Lipocine’s oral testosterone replacement therapy, and related license, supply and distribution arrangements in multiple territories. Recurring financial news includes research and development spending, royalty revenue from TLANDO sales, pipeline prioritization and corporate presentations tied to the company’s oral-delivery programs.
Lipocine Inc. (NASDAQ: LPCN) announced on July 13, 2020, that it has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a Nasdaq letter dated July 9, 2020. This development affirms that the company meets the criteria outlined in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. This compliance is critical for Lipocine's operations and investor confidence, as it avoids potential delisting threats that could negatively impact stock performance.